 |
|
Early stage colon cancer characterized by inactivation of gatekeeper gene
September 10, 2008Singapore scientists report in journal Cancer Cell
The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore scientists report in the Sept. issue of the journal Cancer Cell. Previous studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers.
The inactivation of RUNX3 occurs at a very early stage of colon cancer, according to the Singapore scientists' studies with human tissue samples and animal models.
Because the inactivation of RUNX3 is relatively easy to detect, and it is possible that inactivated RUNX3 can be reactivated, this new research may prove to be a crucial step in the development of an early diagnostic test as well as a therapeutic target for colon cancer.
Prior to these new findings, scientists knew that a tumor suppressor gene called APC is disrupted in most cases of human colon cancer. APC disruption activates bete-catenin and TCF4, a protein complex that plays an important role in cancer development. For decades, this has been considered the molecular basis for colon cancer.
These latest findings are the first to show that the activity of beta- catenin/TCF4 also is inhibited by RUNX3.
The Singapore scientists are based at the National University of Singapore's (NUS) Yong Loo Lin School of Medicine and the Institute of Molecular and Cell Biology (IMCB), one of the 14 research institutes under the country's Agency for Science, Technology and Research (A*STAR).
In an earlier research, the same team of researchers reported that RUNX3 is a major tumor suppressor of gastric cancer.
Leading the Singapore team is Yoshiaki Ito, M.D., NUS Yong Loo Lin Professor in Medical Oncology and a principal investigator at IMCB.
In their latest study, supported by A*STAR, Dr. Ito and his team analyzed animal models as well as tissue samples from patients diagnosed with colon cancer, with prior ethical approval obtained from the Institutional Review Board, to examine how RUNX3 is involved in colon cancer.
"My team and I have been working on our research for the past six years, and we are extremely excited about how our research findings can be translated into practical clinical applications to help patients suffering from cancers such as bladder, breast, colon and lung," said Dr. Ito. "We certainly look forward to our continuous teamwork with our clinical colleagues in improving the lives of cancer patients,"
The body usually has a fail-safe mechanism to get rid of abnormal cells. However, this does not work when RUNX3 is not present. RUNX3 is a gene that acts as a gatekeeper and prevents the uncontrolled growth of cells that may result in cancerous tumor. Disruption of the RUNX3 gene can cause colon cancer as well as many other types of cancers, including those of the bladder, breast, colon and lung.
Said John Wong, M.D., who is Dean of the Yong Loo Lin School of Medicine and director of Singapore's National University Cancer Institute, "Professor Ito's research offers exciting, fresh hope as it lays the groundwork for a diagnostic kit for early detection of colon cancer as well as a possible therapeutic target."
Lee Eng Hin, M.D., Executive Director of A*STAR's Biomedical Research Council, said, "This is a wonderful example of world-class research being done here. As biomedical research efforts in Singapore begin to reap clinically significant outcomes, the working relationships between our scientists and hospital clinicians must be further strengthened. Not only does the success of Professor Ito's work open new doors to colon cancer treatment, it also serves as a leading example for other scientists to follow."
Agency for Science, Technology and Research (A*STAR), Singapore
Because the inactivation of RUNX3 is relatively easy to detect, and it is possible that inactivated RUNX3 can be reactivated, this new research may prove to be a crucial step in the development of an early diagnostic test as well as a therapeutic target for colon cancer.
Prior to these new findings, scientists knew that a tumor suppressor gene called APC is disrupted in most cases of human colon cancer. APC disruption activates bete-catenin and TCF4, a protein complex that plays an important role in cancer development. For decades, this has been considered the molecular basis for colon cancer.
These latest findings are the first to show that the activity of beta- catenin/TCF4 also is inhibited by RUNX3.
The Singapore scientists are based at the National University of Singapore's (NUS) Yong Loo Lin School of Medicine and the Institute of Molecular and Cell Biology (IMCB), one of the 14 research institutes under the country's Agency for Science, Technology and Research (A*STAR).
In an earlier research, the same team of researchers reported that RUNX3 is a major tumor suppressor of gastric cancer.
Leading the Singapore team is Yoshiaki Ito, M.D., NUS Yong Loo Lin Professor in Medical Oncology and a principal investigator at IMCB.
In their latest study, supported by A*STAR, Dr. Ito and his team analyzed animal models as well as tissue samples from patients diagnosed with colon cancer, with prior ethical approval obtained from the Institutional Review Board, to examine how RUNX3 is involved in colon cancer.
"My team and I have been working on our research for the past six years, and we are extremely excited about how our research findings can be translated into practical clinical applications to help patients suffering from cancers such as bladder, breast, colon and lung," said Dr. Ito. "We certainly look forward to our continuous teamwork with our clinical colleagues in improving the lives of cancer patients,"
The body usually has a fail-safe mechanism to get rid of abnormal cells. However, this does not work when RUNX3 is not present. RUNX3 is a gene that acts as a gatekeeper and prevents the uncontrolled growth of cells that may result in cancerous tumor. Disruption of the RUNX3 gene can cause colon cancer as well as many other types of cancers, including those of the bladder, breast, colon and lung.
Said John Wong, M.D., who is Dean of the Yong Loo Lin School of Medicine and director of Singapore's National University Cancer Institute, "Professor Ito's research offers exciting, fresh hope as it lays the groundwork for a diagnostic kit for early detection of colon cancer as well as a possible therapeutic target."
Lee Eng Hin, M.D., Executive Director of A*STAR's Biomedical Research Council, said, "This is a wonderful example of world-class research being done here. As biomedical research efforts in Singapore begin to reap clinically significant outcomes, the working relationships between our scientists and hospital clinicians must be further strengthened. Not only does the success of Professor Ito's work open new doors to colon cancer treatment, it also serves as a leading example for other scientists to follow."
Agency for Science, Technology and Research (A*STAR), Singapore
Colon Cancer Current Events and Colon Cancer News RSSDrop in cancer deaths tied primarily to gains in behavior and screening
Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University.
Combining targeted therapy drugs may treat previously resistant tumors
A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches.
A Simple Blood Test for Colon Cancer
People are often reluctant to undergo a routine but painful colonoscopy ― but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year.
Adalimumab may reduce health-care costs for Crohn's disease patients
Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD). IBD occurs most frequently in people in their late teens and twenties. There have been cases in children as young as two years old and in older adults in their seventies and eighties; men and women have an equal chance of getting the disease.
Washington University scientists first to sequence genome of cancer patient
For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots.
Minority patients discouraged from cancer screening by negative messages
New behavioral science research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, found that constantly emphasizing the negative consequences of a lack of cancer screening among minorities can actually make them less likely to go for screening.
Sibling study could lead to better treatments for inherited form of colon cancer
Researchers at Huntsman Cancer Institute (HCI) believe they may be one step closer to understanding how certain forms of colon cancer develop.
What's the role of beta-catenin in colorectal cancers?
Beta-catenin, a central molecule of the Wnt-signaling pathway was previously known to involve in the tumorigenesis of various gastrointestinal cancers such as gastric cancer and colon cancer.
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
More Colon Cancer Current Events and Colon Cancer News Articles
 | American Cancer Society's Complete Guide to Colorectal Caner by American Cancer Society Don't die of embarrassment--get informed about colorectal cancer Although colorectal cancer is the third most common cancer found in men and women, you may be unaware of your risk and don't know what you can do to prevent this serious disease. You may be too embarrassed to ask your doctor about changes in your bowel habits or get screened for colorectal cancer. American Cancer Society's Complete... |
 | Colon Cancer Answers by Dr. Bruce A. Feinberg One of the greatest failures of public health practices and policy in America is the mismanagement of colon cancer. Despite the fact that colon cancer is 90 percent preventable through safe, accessible, cost-effective screening tests, this terrible disease remains the second leading cause of cancer death. Each year, more than 150,000 Americans will die -- an unnecessary and costly human... |
 | Living With Colon Cancer: Beating the Odds by Eliza Wood Livingston Despite the efforts of Katie Couric to draw attention to the importance of colonoscopy screening for the detection of colon cancer, this cancer still does not receive the publicity devoted to breast, lung, and prostate cancer. Yet colorectal cancer is the third most common malignancy in the world and is the second leading cause of death from cancer next to lung cancer. As a result of the silence... |
 | Why Die of Colon Cancer? by Francis G., M.D. Mackey Cancer of the colon is the second most common cause of cancer death among men and women in North America. However, almost nobody would die of this kind of cancer if they had appropriate colon examinations beginning at age 50. Francis G. Mackey, M.D., a retired cardiologist who has been fighting his own battle with colon cancer for the last two years, has written Why Die of Colon Cancer ?... |
 | What Your Doctor May Not Tell You About(TM) Colorectal Cancer: New Tests, New Treatments, New Hope (What Your Doctor May Not Tell You About...) by Mark Bennett Pochapin Colorectal cancer (cancer of the colon and/or rectum) is the second leading cancer killer in the United States - over 50,000 men and women die from it each year. This is a particularly alarming statistic since it is also one of the most preventable and most treatable forms of cancer. In fact, it is estimated that over one-third of colorectal cancer deaths could easily be avoided. But most people,... |
 | Understanding Colon Cancer by A. Richard, M.D., F.A.C.P. Adrouny For decades, while other cancers grabbed the headlines, colorectal cancer was quietly ignored. The lifetime risk of colorectal cancer in the general population is 2.5 to 5 percent. This means that twenty-five to fifty out of one thousand people will be stricken by this disease. Although data show that in America colorectal cancer incidence and mortality have been waning in recent decades,... |
 | The Colon Cancer Survivors' Guide, Second Edition: Living Stronger, Longer by Curtis Pesmen Based on an award-winning series of Esquire magazine articles on his battle with colon cancer, Pesmen shows how a person stops becomng a patient and starts becoming a survivor. Incluses a chorus of survivors' voices, and casts light on the physical, emotional and psychological needs of those striving to move forward confidently with their lives. New, revised second edition updates treatments and... |
 | Positive Options for Colorectal Cancer: Self-Help and Treatment by Carol Ann Larson Colorectal cancer develops slowly over a period of several years, undetected, usually as polyps. It is a preventable and treatable disease if caught in time, yet most know little about how to read its symptoms. Written for the layperson, this book covers all the uncomfortable questions and answers about the disease, from prevention and warning signs, to screening and diagnosis techniques, to... |
 | What To Do If You Get Colon Cancer: A Specialist Helps You Take Charge and Make Informed Choices by Paul Miskovitz, Marian Betancourt From initial diagnosis to the latest treatments, this encouraging, authoritative guide explores everything you need to know to make informed choices about colon cancer care. You'll learn how colon cancer develops, what to expect from diagnostic tests, and how to choose the best doctors and treatment centers. Here's invaluable information on: Which treatment options work best for different phases... |
 | CANCER, CHEMO AND BEYOND -Survivors and Their Unique Journeys by Donna Richno Diagnosed with stage 4 colon cancer in July 2005, Donna was given no hope of survival from several doctors. At age 41, she refused to give up and kept up the search for the right doctor. This book chronicles her journey through diagnosis, doctor visits, scans, surgeries and chemo treatments. Cancer, Chemo and Beyond also follows the journeys of other survivors of several types of cancer.... |
| © 2008 BrightSurf.com |